Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study
Main finding · Composite of cardioversion, IV antiarrhythmic drug use and AF ablationResult — go to the resultHazard ratio 0.65 95 % CI 0.55–0.76Authors' conclusion
Tirzepatide was significantly associated with reduced AF burden in patients with T2D and AF. These findings suggest a potential therapeutic role, supporting further prospective evaluation. Condensed abstract Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown metabolic and cardiovascular benefits, but its impact on AF burden remains unclear. Using the TriNetX database, this study analyzed 11,194 patients with AF and T2D and found that tirzepatide use was significantly associated with a lower two-year risk of cardioversion, intravenous antiarrhythmic drug use, and AF ablation (HR: 0.65; 95 % CI: 0.55-0.76; P < 0.001). These findings suggest that tirzepatide may offer therapeutic benefits in this high-risk population, warranting further investigation through randomized clinical trials.
Study context
- Population
- Adults with both atrial fibrillation (AF) and T2D diagnosed between January 2022 and February 2025, TriNetX databaseafter matching
- Participants
- 11,194 adults
- Exposure
- Tirzepatide use vs no tirzepatide
- Outcome
- Composite of:
- Cardioversion
- Intravenous antiarrhythmic drug use
- AF ablation
- Follow-up
- two-year
Methodological detailspropensity-score matched, TriNetX database
- Propensity-score matched
- TriNetX database
Main finding
As reported in the abstract
- Cardioversion
- IV antiarrhythmic drug use
- AF ablation
Hazard ratio
0.65
95 % CI 0.55–0.76
P < 0.001
Observational data: associations, not effects.
Secondary outcomes
Secondary outcomes: cardioversion, IV antiarrhythmic therapy, AF ablation, HF, ischemic stroke, all-cause mortality
- Significant findings across all secondary outcomes
Subgroups (AF type, coronary artery disease, CKD, HF, obesity) and sensitivity analyses
- Associations remained consistent across prespecified subgroups and multiple sensitivity analyses
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →